JP2022546400A5 - - Google Patents
Info
- Publication number
- JP2022546400A5 JP2022546400A5 JP2022513090A JP2022513090A JP2022546400A5 JP 2022546400 A5 JP2022546400 A5 JP 2022546400A5 JP 2022513090 A JP2022513090 A JP 2022513090A JP 2022513090 A JP2022513090 A JP 2022513090A JP 2022546400 A5 JP2022546400 A5 JP 2022546400A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical
- liquid formulation
- approximately
- formulation according
- stabilized liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921035059 | 2019-08-30 | ||
| IN201921035059 | 2019-08-30 | ||
| PCT/IB2020/058080 WO2021038532A1 (en) | 2019-08-30 | 2020-08-29 | Novel formulation of highly concentrated pharmacologically active antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022546400A JP2022546400A (ja) | 2022-11-04 |
| JP2022546400A5 true JP2022546400A5 (cg-RX-API-DMAC7.html) | 2023-11-24 |
| JP7792137B2 JP7792137B2 (ja) | 2025-12-25 |
Family
ID=74684124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513090A Active JP7792137B2 (ja) | 2019-08-30 | 2020-08-29 | 高濃度の薬理学的に活性な抗体の新規製剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20220267473A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4021497B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7792137B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020337093B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3152838A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021038532A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021262609A1 (en) | 2020-05-01 | 2022-12-22 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| CA3237624A1 (en) * | 2023-07-28 | 2025-04-24 | Genentech, Inc. | NEW USES FOR OMALIZUMAB |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002213441B2 (en) * | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| MXPA05010555A (es) * | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| NZ595526A (en) | 2007-06-14 | 2013-03-28 | Biogen Idec Inc | Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant |
| PT3345593T (pt) * | 2009-11-13 | 2023-11-27 | Sanofi Aventis Deutschland | Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina |
| AR089434A1 (es) * | 2011-12-23 | 2014-08-20 | Genentech Inc | Procedimiento para preparar formulaciones con alta concentracion de proteinas |
| JP2015509526A (ja) | 2012-03-07 | 2015-03-30 | カディラ ヘルスケア リミティド | 医薬製剤 |
| PE20150964A1 (es) * | 2012-09-07 | 2015-07-25 | Coherus Biosciences Inc | Formulaciones acuosas estables de adalimumab |
| JP2016515120A (ja) | 2013-03-15 | 2016-05-26 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | 抗アルファｖベータ５抗体を用いた急性腎損傷の治療及び予防 |
| RS57864B1 (sr) * | 2013-06-17 | 2018-12-31 | De Staat Der Nederlanden Vert Door De Minister Van Vws Ministerie Van Volksgezondheid Welzijn En Spo | Postupci za sprečavanje agregacije virusnih komponenti |
| WO2016109822A1 (en) | 2014-12-31 | 2016-07-07 | Novelmed Therapeutics, Inc. | Formulation of aglycosylated therapeutic antibodies |
| SG10202012778YA (en) | 2015-12-18 | 2021-01-28 | Astellas Pharma Inc | Pharmaceutical composition comprising anti-human tslp receptor antibody |
| EP3443346B1 (en) * | 2016-04-13 | 2023-08-30 | Medimmune, LLC | Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents |
| US10646569B2 (en) * | 2017-05-16 | 2020-05-12 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| DK3658184T5 (da) | 2017-07-27 | 2024-08-26 | Alexion Pharma Inc | Højkoncentrerede anti-c5-antistofformuleringer |
-
2020
- 2020-08-29 EP EP20858260.1A patent/EP4021497B1/en active Active
- 2020-08-29 JP JP2022513090A patent/JP7792137B2/ja active Active
- 2020-08-29 WO PCT/IB2020/058080 patent/WO2021038532A1/en not_active Ceased
- 2020-08-29 CA CA3152838A patent/CA3152838A1/en active Pending
- 2020-08-29 AU AU2020337093A patent/AU2020337093B2/en active Active
-
2022
- 2022-02-28 US US17/682,314 patent/US20220267473A1/en active Pending
-
2024
- 2024-10-25 US US18/926,965 patent/US20250043027A1/en active Pending